文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

抗 CTLA-4 抗体如何促进癌症免疫？

How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

机构信息

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland Baltimore School of Medicine, Baltimore, MD 21201, USA.

出版信息

Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009.

DOI:10.1016/j.it.2018.10.009
PMID:30497614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6589807/
Abstract

Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.

摘要

抗 CTLA-4 抗体可为一些黑色素瘤患者提供持久的保护。然而，其治疗潜力受到显著的免疫治疗相关不良反应 (irAE) 的限制。在这里，我们认为治疗效果可能基于一种激动剂活性，这种活性与导致 irAE 的拮抗剂活性在根本上不同，并且可以进行治疗区分。

相似文献

[1]
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Trends Immunol. 2018-12

[2]
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.

Trends Pharmacol Sci. 2020-1

[3]
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.

Ann Oncol. 2017-10-1

[4]
CTLA-4: a moving target in immunotherapy.

Blood. 2017-11-8

[5]
Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies.

Immunotherapy. 2013-2

[6]
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Cancer Immun. 2013

[7]
Breakthrough of the year 2013. Cancer immunotherapy.

Science. 2013-12-20

[8]
Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.

Pharm Pat Anal. 2020-9

[9]
Cocktails for cancer with a measure of immunotherapy.

Nature. 2016-4-14

[10]
[Treg cell contribution to anti-CTLA-4 therapeutic effect].

Med Sci (Paris). 2020-1

引用本文的文献

[1]
Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.

Cell Death Dis. 2025-4-13

[2]
Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.

NPJ Vaccines. 2025-2-7

[3]
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.

Cancer Immunol Immunother. 2024-8-9

[4]
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.

Front Immunol. 2024-4-9

[5]
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.

Acta Pharm Sin B. 2023-11

[6]
Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer.

Technol Cancer Res Treat. 2023

[7]
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.

Transl Oncol. 2023-12

[8]
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.

Front Oncol. 2023-5-1

[9]
Vaccination Following Intratumoral Injection of IL2 and Poly-l-lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor Site.

ACS Nano. 2023-6-13

[10]
Antibody-based cancer immunotherapy by targeting regulatory T cells.

Front Oncol. 2023-4-27

本文引用的文献

[1]
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.

Clin Cancer Res. 2018-7-27

[2]
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

Cancer Cell. 2018-6-11

[3]
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

Cell Res. 2018-2-22

[4]
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.

Cell Res. 2018-2-20

[5]
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015-7-2

[6]
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Science. 2014-9-11

[7]
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Cancer Immunol Res. 2013-4-7

[8]
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

J Exp Med. 2013-7-29

[9]
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

J Exp Med. 2013-7-29

[10]
Improved survival with ipilimumab in patients with metastatic melanoma.

N Engl J Med. 2010-6-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索